PDI expecting cuts from AstraZeneca: Reuters

Share this article:
Sales and marketing services provider PDI expects significant reductions in the 800 sales reps it contracts with AstraZeneca, according to a Reuters report. The reductions came as part of discussions with AstraZeneca over the status of fees for service contract sales engagements. AstraZeneca said it would comment further once it has more information about the scope and timing of the changes, the report said.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.